Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Breast Neoplasms 1931Neoplasms 1385Carcinoma, Non-Small-Cell Lung 1324Prostatic Neoplasms 1070Multiple Myeloma 855Leukemia, Myeloid, Acute 759Neoplasm Metastasis 691Colorectal Neoplasms 676Melanoma 666Lung Neoplasms 665Lymphoma 655Leukemia 591Lymphoma, Non-Hodgkin 587Leukemia, Lymphocytic, Chronic, B-Cell 529Ovarian Neoplasms 517Pancreatic Neoplasms 493Precursor Cell Lymphoblastic Leukemia-Lymphoma 471Recurrence 466Myelodysplastic Syndromes 421Lymphoma, Follicular 407Head and Neck Neoplasms 401Glioblastoma 376Carcinoma, Renal Cell 375Lymphoma, Large B-Cell, Diffuse 372Brain Neoplasms 370Hodgkin Disease 352Carcinoma, Hepatocellular 324Squamous Cell Carcinoma of Head and Neck 323Lymphoma, Mantle-Cell 302Sarcoma 281

Interventions

Nivolumab 5Ipilimumab 3relatlimab 1daratumumab 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Has results × Various Advanced Cancer × Clear all
NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed
970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT02632409 2025-10-16

CheckMate 274

Bristol-Myers Squibb

Phase 3 Active not recruiting
709 enrolled 13 charts 1 FDA

Various Advanced Cancer

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed
578 enrolled 19 charts

Various Advanced Cancer

NCT02387996 2022-11-01

A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer

Bristol-Myers Squibb

Phase 2 Completed
270 enrolled 14 charts

Various Advanced Cancer

NCT03130959 2022-08-09

CheckMate 908

Bristol-Myers Squibb

Phase 2 Completed
166 enrolled 33 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡